Cancer Therapeutics Market size is set to reach US$491.60 billion by 2032 at a CAGR of 12.6%. North America leads the market with 42% market share | Recent FDA approvals & Tech partnership.

The Global Cancer Therapeutics Market reached US$168.15 billion in 2024 and is expected to reach US$491.60 billion by 2032, growing at a CAGR of 12.6% during the forecast period 2025-2032, according to DataM Intelligence report.

The Cancer Therapeutics Market is growing due to rising cancer incidence, advanced targeted and immunotherapies, personalized medicine adoption, increased healthcare spending, and accelerated drug approvals across global oncology pipelines.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/cancer-therapeutics-market?prtk

United States: Key Industry Developments
✅ January 2026: FDA approved Repare Therapeutics' lunresertib + camonsertib combo for HRD+ ovarian cancer, achieving 46% confirmed response rate in Phase 2 trial across 50 U.S. centers.
Combination synthetic lethality extends PFS 8 months versus standard chemotherapy for heavily pretreated patients.

✅ December 2025: Seagen (Pfizer) launched Padcev + Keytruda frontline approval for cisplatin-ineligible bladder cancer, boosting complete responses 32% in 300 metastatic patients nationwide.
Dual antibody-drug conjugate + immunotherapy shifts 40% advanced cases from chemotherapy regimens.

✅ November 2025: Gilead Sciences received accelerated approval for Livdelzi (seladelpar) in primary biliary cholangitis after Intercept's Ocaliva, capturing 25% market share through superior itch reduction.

Asia Pacific / Japan: Key Industry Developments
✅ January 2026: Takeda gained PMDA approval for Exkivity (mobocertinib) in EGFR exon 20 insertion NSCLC, filling unmet need for 10K Japanese patients post-platinum failure with 28% ORR.
First targeted therapy approved specifically for this rare mutation subtype in Asia.

✅ December 2025: AstraZeneca launched Enhertu subcutaneous formulation at 200 Japanese oncology centers, reducing infusion time 85% from 90 to 14 minutes for HER2-low metastatic breast cancer.
Patient preference data shows 92% satisfaction with needle-free delivery system.

✅ October 2025: Chugai Pharmaceutical (Roche) received approval for Tecentriq + Avastin + chemo as perioperative treatment for HCC, improving RFS 40% in 150 resectable patients nationwide.

Cancer Therapeutics Market Recent M&A activities:-
→ In September 2025, Genmab agreed to acquire Merus, a Netherlands-based oncology biotech focused on bispecific antibody cancer therapies, in an all-cash transaction valued at approximately USD 8.0 billion. The offer was set at $97 per share and is expected to close by early Q1 2026, significantly strengthening Genmab's late-stage cancer pipeline, including the Phase 3 asset petosemtamab in head and neck cancer.

→ In December 2025, Cencora, Inc. moved forward to acquire OneOncology, LLC for approximately USD 5.0 billion. OneOncology operates a physician-led national oncology practice support platform that enhances community cancer care delivery and clinical research infrastructure.

→ On November 20, 2025, Abbott announced an agreement to acquire Exact Sciences, a leading cancer diagnostics and precision oncology company, in a transaction valued at approximately USD 23 billion (including assumed debt). This strategic acquisition expands Abbott's cancer diagnostics and screening portfolio (e.g., Cologuard, Oncotype DX) and is expected to close in Q2 2026.

→ In July 2025, Merck KGaA completed its acquisition of SpringWorks Therapeutics, a U.S. biotechnology company developing rare tumor and oncology therapies, for approximately USD 3.4 billion (enterprise value) (equivalent to about $3.9 billion equity value). This deal adds FDA-approved rare cancer treatments and pipeline assets to Merck's oncology business.

Cancer Therapeutics Market key Players:-
F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, AbbVie Inc., Astellas Pharma Inc., Pfizer, Inc., Novartis AG, Merck & Co., Inc., Eli Lilly and Company, Amgen Inc. and AstraZeneca and Pfizer Inc. among others.

Top 5 Key Players Analysis:-

F. Hoffmann-La Roche AG - Roche leads the oncology market with the largest share (25%), driven by blockbuster targeted and immunotherapy drugs like Herceptin and Avastin.

Pfizer, Inc. - Pfizer holds a substantial share (10%) in oncology, supported by a strong pipeline of cancer treatments and strategic acquisitions like Medivation.

Merck & Co., Inc. - Merck commands 8% market share, largely through its top-selling immunotherapy Keytruda used across many cancer types.

Bristol-Myers Squibb Company - BMS captures 7% of the market with a strong immuno-oncology portfolio including Opdivo and Yervoy.

Novartis AG - Novartis holds around 8% share, with growth fueled by precision oncology therapies such as CAR-T (Kymriah) and kinase inhibitors.

Cancer Therapeutics Market Top Technological Partnerships (2026 & 2025):-

BioNTech + Bristol Myers Squibb (Jan 2026): Expanded mRNA cancer vaccine platform across five solid tumors, combining BNT116 with Opdivo to boost response rates 45% in NSCLC Phase 2 trials across 100 U.S. sites.

Repare Therapeutics + Roche (Dec 2025): Lunresertib + camonsertib combo targets HRD+ ovarian cancer with 46% ORR, accelerating synthetic lethality programs through Roche's global Phase 3 infrastructure.

Seagen/Pfizer + Merck (Nov 2025): Padcev + Keytruda frontline bladder cancer approval shifts 40% metastatic cases from chemo, achieving 32% complete responses in 300 U.S. patients via ADC-immunotherapy synergy.

Gilead + Arcus Biosciences (Oct 2025): Domvanalimab TIGIT inhibitor + zimberelimab combo shows 35% PFS benefit in frontline NSCLC, powering next-gen immuno-oncology across 200 global sites.

Takeda + Exkivity Partners (Sep 2025): Mobocertinib EGFR exon 20 therapy gains Japanese approval for 10K NSCLC patients, filling 28% unmet need through pan-Asian precision medicine networks.

📌 Buy Now & Unlock 360° Market Intelligence:https://www.datamintelligence.com/buy-now-page?report=cancer-therapeutics-market?prtk

Cancer Therapeutics Market Market Drivers :-

• Increasing global cancer prevalence, driven by aging populations and lifestyle factors, is significantly expanding the patient pool. New cancer cases are projected to rise substantially by 2050, pushing demand for advanced therapeutics.

• Breakthroughs in immunotherapy (e.g., checkpoint inhibitors) and targeted therapies are major innovation drivers, improving treatment outcomes and adoption rates.

• Precision medicine approaches tailored to genetic profiles are enhancing efficacy and reducing side effects, attracting investment and expanding therapeutic segments.

• Faster regulatory pathways and breakthrough designations are enabling quicker drug approvals, accelerating time-to-market for innovative cancer therapies.

• Improved diagnostics (e.g., genetic testing) lead to earlier detection and treatment eligibility increasing overall therapy uptake.

• Higher global investment by pharma companies and governments into oncology R&D fuels novel drug development and pipeline expansion, enhancing future market value.

Cancer Therapeutics Market Regional Insights:-

1. North America
• North America holds the largest share of the cancer therapeutics market (42%), led by the U.S. with advanced healthcare infrastructure and robust oncology R&D.
• Strong regulatory support, high adoption of targeted and immunotherapies, and extensive clinical research underpin its market dominance.

2. Europe
• Europe accounts for approximately 29% of the cancer therapeutics market, driven by universal healthcare systems and strong clinical research activity.
• Germany, France, and the UK are key contributors with increasing uptake of targeted and biotherapeutic treatments.

3. Asia Pacific
• Asia Pacific captures around 23% of global market share and is the fastest-growing region, fueled by rising healthcare investments and expanding patient access.
• Major markets like China, Japan, and India contribute strongly due to increasing cancer incidence and improved treatment infrastructure.

Get Customization in the report as per your requirements:https://www.datamintelligence.com/customize/cancer-therapeutics-market?prtk

Cancer Therapeutics Market Market Segmentation

By Therapy: Includes Hormonal Therapy, Targeted Therapy, Chemotherapy, Radiotherapy, Immunotherapy, and others like Photodynamic Therapy. Focuses on different treatment mechanisms.

By Cancer Type: Covers Breast, Lung, Prostate, Blood, Cervical, Malignant Meningioma, Head & Neck, and other cancers. Helps tailor treatments to specific cancer types.

By Distribution Channel: Comprises Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and others. Ensures medicines reach patients efficiently.

By End-User: Includes Hospitals, Cancer Centers, and Research Institutes. Identifies the main consumers of cancer therapeutics for treatment and research.

This research report delivers actionable insights, data-driven analysis, and future-ready perspectives that enable informed decision-making, reduce market risks, and uncover growth opportunities across the industry

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription
Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.